Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Arrowhead Pharmaceuticals to Present at Upcoming September 2018 Conferences

Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to present at the following upcoming events:

Arrowhead Pharmaceuticals to Present at Upcoming September 2018 Conferences

Pasadena. CA | Posted on August 31st, 2018

Annual B. Riley FBR Healthcare Conference– New York, September 4, 2018

Bruce Given, M.D., Arrowhead’s chief operating officer, and Vincent Anzalone, CFA, vice president of investor relations, will participate in three panel discussions

18th World Gastroenterologists Summit – Auckland, New Zealand, September 7-8, 2018

September 7, 09:45 a.m. NZST – Dr. Given will deliver a keynote presentation titled, “Hepatitis B in focus: New biology, new targets and real hope for finite therapy”

European Respiratory Society International Congress 2018 – Paris, September 15-19, 2018

September 16, 12:15 p.m. CEST –Erik Bush, Ph.D., Arrowhead’s director of extra-hepatic targeting, will deliver an oral presentation titled, “Targeting ENaC with an epithelial RNAi trigger delivery platform for the treatment of cystic fibrosis”

Antivirals: Targeting HBV and Beyond – Boston, September 25, 2018

September 25, 12:00 p.m. EDT –James Hamilton, M.D., Arrowhead’s vice president of clinical development, will deliver an oral presentation titled, “Using siRNA to target the HBV transcriptome”

A copy of presentation materials may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website after the presentations conclude.

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts .

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400

or
Investors and Media:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578

www.lifesciadvisors.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Shape-shifting sensors could catch early signs of cancer October 19th, 2018

Study provides insight into how nanoparticles interact with biological systems: Findings can help scientists engineer nanoparticles that are ‘benign by design’ October 18th, 2018

Iran Produces Cooling Fabrics Using Nanotechnology October 17th, 2018

Iran World’s Second Largest Producer of Nano-Catalysts October 17th, 2018

Nanomedicine

Arrowhead Pharmaceuticals Hosts R&D Day on Pipeline of RNAi Therapeutics October 17th, 2018

Big award enables study of small surfaces: Rice U.'s Matt Jones wins Packard Fellowship to view nanoscale chemical reactions October 15th, 2018

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-ANG3 October 15th, 2018

180 Degree Capital Corp. Announces New Portfolio Holdings – Airgain, Inc., EMCORE Corporation, Lantronix, Inc. and PDL BioPharma, Inc. October 12th, 2018

Announcements

Shape-shifting sensors could catch early signs of cancer October 19th, 2018

Study provides insight into how nanoparticles interact with biological systems: Findings can help scientists engineer nanoparticles that are ‘benign by design’ October 18th, 2018

Iran Unveils Its First Homegrown 3D Nano Printer October 17th, 2018

Fat-Repellent Nanolayers Can Make Oven Cleaning Easier October 17th, 2018

Events/Classes

Arrowhead Pharmaceuticals Hosts R&D Day on Pipeline of RNAi Therapeutics October 17th, 2018

Iran Produces Cooling Fabrics Using Nanotechnology October 17th, 2018

Iran World’s Second Largest Producer of Nano-Catalysts October 17th, 2018

Iran Unveils Its First Homegrown 3D Nano Printer October 17th, 2018

Nanobiotechnology

Arrowhead Pharmaceuticals Hosts R&D Day on Pipeline of RNAi Therapeutics October 17th, 2018

Big award enables study of small surfaces: Rice U.'s Matt Jones wins Packard Fellowship to view nanoscale chemical reactions October 15th, 2018

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-ANG3 October 15th, 2018

180 Degree Capital Corp. Announces New Portfolio Holdings – Airgain, Inc., EMCORE Corporation, Lantronix, Inc. and PDL BioPharma, Inc. October 12th, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project